Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Hyaluronic Acid Assays: Turbidimetric or Enzyme-Based Immune Assay? A Method Comparison Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Indexing glomerular filtration rate to body surface area: clinical consequences

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Arno Floore
  • Albertus Hesselink
  • Anja Oštrbenk
  • Elia Alcaniz
  • Beate Rothe
  • Helle Pedersen
  • Montserrat Torres Hortal
  • Saskia Doorn
  • Wim Quint
  • Karl Ulrich Petry
  • Mario Poljak
  • Kate Cuschieri
  • Jesper Bonde
  • Silvia de Sanjosé
  • Maaike Bleeker
  • Daniëlle Heideman
Vis graf over relationer

BACKGROUND: HPV-based cervical screening detects women at an increased risk of cervical cancer and precancer. To differentiate among HPV-positive women those with (pre)cancer, triage testing is necessary. The detection of cancer-associated host-cell DNA methylation (FAM19A4 and hsa-mir124-2) in cervical samples has shown valuable as triage test. This multicenter study from 6 collaborating European laboratories and one reference laboratory was set out to determine the intra- and inter-laboratory agreement of FAM19A4/mir124-2 DNA methylation analysis utilizing the QIAsure Methylation Test.

METHODS: Agreement analysis for the QIAsure Methylation Test was assessed on high-risk HPV-positive cervical specimens (n = 1680) both at the level of the assay and at the full workflow, including bisulfite conversion.

RESULTS: Intra- and inter-laboratory assay agreement were 91.4% (534/584; 95% CI 88.9-93.5; κ = 0.82) and 92.5% (369/399; 95% CI 90.0-94.7; κ = 0.83), respectively. The inter-laboratory workflow (bisulfite conversion and assay combined) agreement was 90.0% (627/697; 95% CI 87.5%-92.0%; κ = 0.76).

CONCLUSION: These data show that the QIAsure Methylation Test performs robust and reproducible in different laboratory contexts. These results support the use of the QIAsure Methylation Test for full molecular screening for cervical cancer, including primary HPV testing and triage testing by methylation analysis.

OriginalsprogEngelsk
Artikelnummere22854
TidsskriftJournal of Clinical Laboratory Analysis
Vol/bind33
Udgave nummer4
ISSN0887-8013
DOI
StatusUdgivet - maj 2019

ID: 56533858